UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Core Viewpoint - A shareholder has filed a securities class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging misrepresentations related to the drug AMT-130 for Huntington's Disease treatment [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the development of AMT-130, which is intended for treating Huntington's Disease [4]. - Investors who wish to serve as lead plaintiffs must file papers by April 13, 2026, and participation does not require serving as lead plaintiff [3]. Group 2: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large pension funds [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [5].